| Old Articles: <Older 1381-1390 Newer> |
|---|
 |
Insurance & Technology
August 25, 2004
Marianne Kolbasuk McGee |
EMR Initiative: BCBSMA Steals a March One Massachusetts community is going to find out if electronic medical records really can deliver revolutionary improvements in the quality and cost of healthcare.   |
BusinessWeek
September 6, 2004
Mara Der Hovanesian |
Ready to Rebound at Angiotech Boston Scientific's July 2 recall of its drug-coated stents has sent shares tumbling 17%. Some analysts call it a buying opportunity. And, they say, little-known Angiotech Pharmaceuticals, a specialty outfit in Vancouver, may be an even better bet. |
The Motley Fool
August 24, 2004
Jeff Hwang |
Trial Letdown Hits Possis Medical Disappointing trial data regarding the AngioJet catheter takes a 38% bite out of Possis Medical's stock. |
The Motley Fool
August 23, 2004
Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
The Motley Fool
August 20, 2004
Ben McClure |
Icahn Targets Mylan The billionaire's presence at the generic-drug maker Mylan could be bad news for management there, but good news for shareholders. |
The Motley Fool
August 20, 2004
Rich Smith |
Let Kensey Cure Your Portfolio The biomedical products maker is a profit-making machine. This small cap reported outsized profits for fiscal 2004. |
The Motley Fool
August 19, 2004
Charly Travers |
1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL. |
The Motley Fool
August 19, 2004
Charly Travers |
Myriad's Making Hope Possible This small biotech provides screens that can help catch cancer. Even with solid growth of product revenue, losses could continue to increase as Myriad moves more drugs into clinical development while it transitions into a drug developer. |
Bio-IT World
August 18, 2004
John Russell |
Special Report: 2004: A Best Practices Odyssey Grand Prize Winners: Drug Discovery & Development: Iconix Pharmaceuticals... IT Infrastructure & Informatics: Baylor College of Medicine, Department of Molecular and Cellular Biology Core Lab... etc. |
Bio-IT World
August 18, 2004
Anthony Strattner |
Opportunity to Gain or Lose A keynote speaker at Best Practices ceremony asserts that drug-development science -- those activities that go beyond translational science and into product testing and commercialization -- has stagnated, causing a pipeline problem. |
| <Older 1381-1390 Newer> Return to current articles. |
